Welcome to BioSeeker Group!

The Complete Guide to Targeted Therapies in Oncology: A World Review

Additional Information

Published Date Dec 19, 2006
Pages 550
PDF Fact Sheet View Fact Sheet for the report The Complete Guide to Targeted Therapies in Oncology: A World Review in PDF
Format PDF
Publisher BioSeeker Group

Availability: In stock

$4,950.00

Quick Overview

In this comprehensive report covering targeted therapies in oncology, BioSeeker Group has analyzed apoptopic agents, protein kinase inhibitors, anti-angiogenic and vascular targeting agents, immunostimulators, antibodies and vaccines in oncology.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to The Complete Guide to Targeted Therapies in Oncology: A World Review.

    To find out more about The Complete Guide to Targeted Therapies in Oncology: A World Review, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that The Complete Guide to Targeted Therapies in Oncology: A World Review is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Introduction

The dogma for treatment of cancer has changed, with the cytotoxic drugs used in chemotherapy regimes set to lose their dominance and be used alongside targeted therapies that are being developed with the aim of more specifically targeting cancer cells.

Research and analysis highlights

In this comprehensive report covering targeted therapies in oncology, BioSeeker Group has analyzed apoptopic agents, protein kinase inhibitors, anti-angiogenic and vascular targeting agents, immunostimulators, antibodies and vaccines in oncology.
This extensive 550+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the mentioned key oncology targeted therapy areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
The number of targeted therapy drugs has risen sharply, as have the number of targets. The fiercest competition in oncology targeted therapy is pointed out and how several big pharma companies are out hunting for promising technology and drugs to complement their internal pipeline.

Scope of this report

  • In-depth competitive landscape assessment of the targeted oncology market place; Including more than 340 drugs and pharmaceutical companies
  • Thorough review of six major targeting strategies in oncology: Apoptopic agents, Protein kinase inhibitors, Anti-angiogenic and vascular targeting agents, Immunostimulators, Antibodies and Vaccines
  • Progress analysis of major cancer indications for respective targeting strategy, including players, drugs, clinical progress and pitfalls
  • Includes more than 120 Tables, 60 Boxes and close to 40 Figures

Key reasons to read this report

  • Understand the clinical and strategic challenges to the commercialization of six major targeting strategies in oncology
  • Assess opportunities and risks for the continued development of targeting agents in major cancer indications.
  • Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to The Complete Guide to Targeted Therapies in Oncology: A World Review.
    To find out more about The Complete Guide to Targeted Therapies in Oncology: A World Review, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that The Complete Guide to Targeted Therapies in Oncology: A World Review is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Oncology' category:


Cancer Antibodies: Drug Target Atlas and Competitive Outlook
This report is a new and unique way of stratifying and analyzing the global antibody pipeline in cancer towards personalized medicine and presents actionable analysis Learn More


Triple Analysis: Lung Cancer, Angiogenesis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Learn More

Other selected research from the 'Vaccines' category:


Cancer Vaccines Drug Pipeline Update
BioSeeker Group have identified 314 companies plus partners who are today developing 386 cancer vaccine drugs in 784 developmental projects in cancer across 195 different targets. In addition, there are 8 suspended drugs and another 208 drugs where development has been ceased. Learn More


Competitive Outlook on Non-Antibody Based Cancer Vaccines
Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications. Learn More

Other selected research from the 'Targeted' category:


Target Atlas in Oncology Drug Development: Major Tumor Types
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances. Learn More


The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics
The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody-based technologies have rapidly developed into one of the major market segments of the pharmaceutical industry. Learn More